Laurus Labs
LAURUSLABS
Laurus Labs Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | - | 8,60,555 |
| Weekly | 2.17% | 99,97,248 |
| Monthly | 6.52% | 3,41,05,483 |
Laurus Labs Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| LAURUSLABS | - | 2.17% | 6.52% |
| Index | - | - | - |
| Peer Avg. | - | 5.43% | 11.51% |
Laurus Labs Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| LAURUSLABS | 40.29 | 9.44 | 13.32 | 26.35 | 24.75 | 0.56 |
| Index | 35.44 | 5.98 | 16.81 | 16.99 | 18.41 | 1.19 |
| Peer Avg. | 39.55 | 4.75 | 12.35 | 13.59 | 17.02 | 0.87 |
Laurus Labs Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | 0.62% | -18.47% | 26.35% | 24.75% |
| FY '20-21 | 70.23% | 271.72% | 43.74% | 39.21% |
| FY '19-20 | 24.32% | 176.69% | 15.56% | 14.27% |
Laurus Labs Shareholding Pattern
Laurus Labs Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 4,821.31 | 3,467.49 | 1,372.24 | 791.26 |
| FY '20-21 | 4,791.11 | 3,260.84 | 1,555.77 | 969.97 |
| FY '19-20 | 2,814.53 | 2,247.14 | 573.25 | 261.16 |
Laurus Labs Peer Comparison
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| LAURUSLABS | 4,821.31 | 3,467.49 | 1,372.24 | 791.26 |
| JBCHEPHARM | 2,307.06 | 1,781.39 | 565.10 | 373.52 |
| IPCALAB | 5,581.70 | 4,357.43 | 1,341.09 | 890.95 |
Laurus Labs Share Price
Laurus Labs Limited is an Indian pharmaceutical and biotechnology company. The company manufactures active ingredients (API) for antiretroviral (ARV), oncology, cardiovascular, diabetes, asthma and gastroenterology. The company also develops and manufactures oral solid formulations, provides contract research and manufacturing services (CRAMS) to other global pharmaceutical companies, and produces specialty ingredients for nutraceuticals, nutraceuticals and cosmetics. The company operates through four business units covering various therapeutic applications, including Generics API, which develops, manufactures and sells APIs and advanced intermediates; Generics Finished Dosage Form (FDF), which develops and manufactures oral solid formulations; Synthesis, which is the main starting materials, intermediates and APIs for New Chemical Entities (NCEs), and Bio, which deals with recombinant products.